Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.60 |
| ▸ | WDR5 | P61964 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | ENGASE | Q8NFI3 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.60 |
| ▸ | NPY1R | P25929 | 2/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.60 |
| ▸ | HTR3A | P46098 | 2/20 | 0.60 |
| ▸ | FASN | P49327 | 2/20 | 0.60 |
| ▸ | SARM1 | Q6SZW1 | 2/20 | 0.60 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rabeprazole SCHEMBL2998947 | 1.00 | KMT2A (0.60) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Rabeprazole SCHEMBL2998946 | 1.00 | KMT2A (0.60) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Dexrabeprazole SCHEMBL22189141 | 1.00 | KMT2A (0.60) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Rabeprazole SCHEMBL140495 | 1.00 | KMT2A (0.60) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Rabeprazole SCHEMBL27964348 | 0.99 | KMT2A (0.59) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Dexrabeprazole SCHEMBL30945135 | 0.99 | KMT2A (0.61) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Dexrabeprazole SCHEMBL30019061 | 0.99 | KMT2A (0.61) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Dexrabeprazole SCHEMBL4946138 | 0.99 | KMT2A (0.61) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Rabeprazole SCHEMBL29374701 | 0.99 | KMT2A (0.61) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Rabeprazole SCHEMBL23336 | 0.99 | KMT2A (0.61) | KMT2ACYP2C9WDR5LMNAENGASE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 678 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120131579-A | Enteric coated tablet containing rabeprazole sodium and application thereof | 郑州大学第一附属医院 | 2025-06-13 | — | — | CN | claimed |
| CN-118903309-A | Application of compound PIANZAIHUANG buccal tablet in preparing medicine for preventing and/or treating laryngopharyngeal reflux disease | 漳州片仔癀药业股份有限公司 | 2024-11-08 | — | — | CN | claimed |
| CN-118311216-B | Rapid determination method for dissolution rate of sodium rabeprazole enteric-coated tablets | 湖南明瑞制药股份有限公司 | 2024-09-13 | — | — | CN | claimed |
| CN-118311216-A | Rapid determination method for dissolution rate of sodium rabeprazole enteric-coated tablets | 湖南明瑞制药股份有限公司 | 2024-07-09 | — | — | CN | claimed |
| CN-118258939-A | Method for detecting levo-rabeprazole and dextro-rabeprazole in human plasma | 烟台大学 | 2024-06-28 | — | — | CN | claimed |
| CN-116236580-B | Application of old medicines such as auranofin and the like and compositions thereof in resisting single positive strand RNA viruses | 中国科学院上海药物研究所 | 2024-05-24 | — | — | CN | claimed |
| CN-118010878-A | Determination method and application of impurities in sodium rabeprazole enteric-coated preparation | 丽珠集团丽珠制药厂 | 2024-05-10 | — | — | CN | claimed |
| CN-117949559-A | Method for testing related substances in sodium rabeprazole enteric-coated tablets | 湖南九典制药股份有限公司 | 2024-04-30 | — | — | CN | claimed |
| CN-114609268-B | Detection method for related substances in sodium rabeprazole bulk drug | 南京海纳医药科技股份有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-115252610-B | Use of proton pump inhibitors against coronaviruses | 上海科技大学 | 2024-03-26 | — | — | CN | claimed |
| US-20060178406-A1 | Process for production of sulfoxide derivatives or salts thereof in the amorphous state | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-08-10 | — | — | US | claimed |
| CN-1729974-A | Soft capsule of sodium rabeprazole and its preparation process | BEIJING LANBEIWANG MEDICINE TE (CN) | 2006-02-08 | — | — | CN | claimed |
| EP-1607395-A1 | PROCESS FOR PRODUCTION OF SULFOXIDE DERIVATIVES OR SALTS THEREOF IN THE AMORPHOUS STATE | Eisai Co., Ltd. (JP) | 2005-12-21 | — | — | EP | claimed |
| US-20050234103-A1 | Crystalline forms of rabeprazole sodium | DR. REDDY'S LABORATORIES, INC. | 2005-10-20 | — | — | US | claimed |
| EP-1487820-A1 | CRYSTALLINE FORMS OF RABEPRAZOLE SODIUM | Dr. Reddy's Laboratories Ltd. (IN) | 2004-12-22 | — | — | EP | claimed |
| EP-1000943-B1 | Sulfoxide compounds and acetone complexes, and a process for producing the same | EISAI CO LTD (JP) | 2004-02-18 | — | — | EP | claimed |
| WO-2003082858-A1 | CRYSTALLINE FORMS OF RABEPRAZOLE SODIUM | DR. REDDY'S LABORATORIES LIMITED (IN) | 2003-10-09 | — | — | WO | claimed |
| US-6545024-B1 | Complexing acetone with sulfoxides such as Rabeprazole, Lansoprazole, Omeprazole or Pantoprazole; inhibitors of gastric acid secretion and anti-ulcer agents or as intermediates for production of medicines | EISAI CO., LTD. (JP) | 2003-04-08 | — | — | US | claimed |
| US-6180652-B1 | ANTIULCER, ANTISECRETORY AGENTS | EISAI CO., LTD. (JP) | 2001-01-30 | — | — | US | claimed |
| EP-1000943-A1 | Sulfoxide compounds and acetone complexes, and a process for producing the same | Eisai Co., Ltd. (JP) | 2000-05-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234103-A1 | Crystalline forms of rabeprazole sodium | RAB7A, RABL3, RAB27A | KMT2A 3014/4885CYP2C9 79/4885WDR5 1450/4885 |
| US-20060178406-A1 | Process for production of sulfoxide derivatives or salts thereof in the amorphous state | MSRB3, SCLY, AS3MT | KMT2A 804/4885CYP2C9 1086/4885WDR5 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.